Solid Biosciences
SLDB
104 hedge funds and large institutions have $437M invested in Solid Biosciences in 2021 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 32 increasing their positions, 21 reducing their positions, and 11 closing their positions.
264% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 11
156% more call options, than puts
Call options by funds: $5.35M | Put options by funds: $2.09M
52% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 21
39% more funds holding
Funds holding: 75 → 104 (+29)
6% more capital invested
Capital invested by funds: $414M → $437M (+$23.7M)
0.5% more ownership
Funds ownership: 4.29% → 4.79% (+0.5%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31M |
| 2 |
PA
Perceptive Advisors
New York
|
+$19.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$18.3M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.6M |
| 5 |
AG
Artal Group
Luxembourg
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.78M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
-$5.64M |
| 3 |
ACM
Atika Capital Management
New York
|
-$1.92M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.55M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.13M |
SLDB Hedge Fund Activity: Q1 2021 in Review
104 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q1 2021, worth a combined $437M — up 5.7% from $414M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new SLDB positions and 11 closed out — a net gain of 29 holders — while 32 added to existing stakes and 21 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $31M. The largest seller was Millennium Management, cutting an estimated $5.78M.
- 104 institutional investors held Solid Biosciences (SLDB) as of Q1 2021, up from 75 in Q4 2020.
- Funds reported $437M of Solid Biosciences stock for Q1 2021, up 5.7% quarter-over-quarter.
- 40 funds opened new Solid Biosciences positions in Q1 2021 and 11 closed out, a net change of +29 holders.
- The largest Solid Biosciences buyer in Q1 2021 was T. Rowe Price Associates, an estimated $31M added.
- The largest Solid Biosciences seller in Q1 2021 was Millennium Management, an estimated $5.78M sold.
Based on aggregated 13F filings for Q1 2021.